Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

FDA Discloses Safety Reviews Of COX-2s Arcoxia, Prexige and Parecoxib

Feb 14 2005

• By The Pink Sheet

Related Content

Prexige TARGET Study: Not Quite A Bull’s-Eye For Novartis

Aug 23 2004

Merck Arcoxia 6,000-Patient Trial Will Study GI, Cardiac Events

Jun 17 2002

Vioxx Cardiovascular Risk Is Unique To Molecule, Pfizer And Novartis Tell FDA

Feb 14 2005

Additional Topics

BioPharmaceutical

More from Archive

More from Pink Sheet

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window